March 2026 Q&A | GLP-1s, GH Peptides, Healing, Autoimmune & More | Hunter Williams Hunter Williams answers your March 2026 submitted questions across six categories GLP-1s, growth hormone secretagogues, healing & injury recovery, metabolic peptides, men's health, and autoimmune support
The warning letter focused heavily on sterility assurance for injectable drug products, including GLP-1 medications used for weight loss
PlexusDx compounds semaglutide in licensed 503A pharmacies and provides storage guidance tailored to your climate and lifestyle
As the disease progresses however it becomes increasingly non-responsive to therapeutic interventions [92,93]
Medullary thyroid carcinoma history
The classification helps answer the question: "What am I actually taking, and how does it compare to what I read about online?" [Diagram suggestion: Four-quadrant matrix with axes labeled "Receptor target" (pure GLP-1 vs multi-agonist) and "Approval status" (FDA-approved vs compounded), with all medications plotted in their respective quadrants] The pattern we see in FormBlends refill data: patients often start on compounded semaglutide (Tier 4), then switch to brand-name Wegovy (Tier 1) when insurance coverage becomes available, then switch to tirzepatide (Tier 3) if weight loss plateaus
